Full year 2025 total revenue decreased to $69.6 million from $84.6 million in 2024. Clinical test revenue more than doubled in 2025 to $2.0 million from $0.8 million in 2024. Clinical test volume surged nearly 400% in 2025 to 16,233 tests, up from 3,285 in 2024. Fourth quarter 2025 total revenue increased to $17.3 million from $16.8 million in Q4 2024. Q4 2025 clinical test volume was 6,183 tests, a 41% sequential increase over Q3 2025. Secured Medicare coverage for breast cancer recurrence surveillance in Q4 2025 and Stage I to III non-small cell lung cancer (NSCLC) in Q1 2026. Ended 2025 with approximately $240 million in cash, cash equivalents, and short-term investments. Full year 2026 revenue guidance is $78.0 to $80.0 million, with clinical revenue projected to grow approximately five-fold to $10.0 to $11.0 million. Expected 2026 clinical volume is 43,000 to 45,000 tests. Full year 2026 gross margin guidance is 15% to 20%. Full year 2026 net loss is projected at approximately $105.0 million, with cash usage of approximately $100.0 million.